Form 4: Soleno Therapeutics Executive Acquires 145,000 Stock Options
SEC Form 4 Filing
Raymond W. Urbanski, Chief Development Officer of Soleno Therapeutics, acquired 145,000 stock options on August 13, 2024.
Summary
- Raymond W. Urbanski, the Chief Development Officer of Soleno Therapeutics, filed a Form 4 on August 23, 2024, reporting a transaction.
- On August 13, 2024, Urbanski acquired 145,000 stock options with an exercise price of $49.52.
- These options vest over time, with one-fourth vesting on August 12, 2025, and the remainder vesting monthly thereafter, contingent on continued service.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing related to stock option grants, which is neutral in sentiment.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to monitor potential alignment of interests between management and shareholders.
Stakeholder Impact
- The acquisition of stock options by a key executive could potentially align their interests more closely with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 08/13/2024 | Date of the stock option acquisition. |
| 08/12/2025 | Date when one-fourth of the stock options begin to vest. |
| 08/23/2024 | Date of Form 4 filing. |
| 08/13/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.